Form 4: Allogene Therapeutics EVP of R&D Sells Shares to Cover Tax Obligations

Zachary Roberts, EVP of R&D at Allogene Therapeutics, sold 27,199 shares of common stock on January 21, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On January 21, 2025, Zachary Roberts, the EVP of R&D at Allogene Therapeutics, sold 27,199 shares of Allogene common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $1.78, with individual transactions ranging from $1.78 to $1.805.
• Following the transaction, Roberts directly owns 488,054 shares of Allogene Therapeutics.
• Roberts has granted a power of attorney to Earl Douglas, Geoffrey Parker, Annie Yoshiyama, and Lillian Smith to execute and file Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to an insider transaction. The sale of shares to cover tax obligations is a neutral event and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives and their potential impact on the stock's price.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant long-term effect.

Key Dates